Wrocław University Of Environmental And Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrocław University Of Environmental And Life SciencesfiledCriticalWrocław University Of Environmental And Life Sciences
Priority to PL425549(22)20180515ApriorityCriticalpatent/PL238122B1/en
Publication of PL425549A1publicationCriticalpatent/PL425549A1/en
Publication of PL238122B1publicationCriticalpatent/PL238122B1/en
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur
(AREA)
Abstract
Zgłoszenie dotyczy optycznie czynnego cis-(4R,5R,6S)-5-(1-bromoetylo)-4-(2',5'-dimetylofenylo)-dihydrofuran-2-onu o wzorze 1, oraz sposobu jego otrzymywania. Sposób ten polega na tym, że kwas (S,E)-3-(2',5'-dimetylofenylo)-heks-4-enowy poddaje się reakcji bromolaktonizacji otrzymując mieszaninę produktów, z której następnie metodą chromatografii kolumnowej wydziela się w postaci czystej cis-(4R,5R,6S)-5-(1-bromoetylo)-4-(2',5'-dimetylofenylo)-dihydrofuran-2-on.The application relates to optically active cis- (4R, 5R, 6S) -5- (1-bromoethyl) -4- (2 ', 5'-dimethylphenyl) -dihydrofuran-2-one of the formula I and a method for its preparation. In this method, (S, E) -3- (2 ', 5'-dimethylphenyl) -hex-4-enoic acid is subjected to a bromolactonization reaction to obtain a mixture of products, which is then separated by column chromatography in pure form. cis- (4R, 5R, 6S) -5- (1-bromoethyl) -4- (2 ', 5'-dimethylphenyl) -dihydrofuran-2-one.
PL425549(22)20180515A2018-05-152018-05-15Cis-(4R,5R,6S)-5-(1-bromethyl)-4-(2',5'-dimethylphenyl)-dihydrofuran-2-one and method for obtaining it
PL238122B1
(en)
SOLID ACID FORMS 2-((4-((S)-2-(5-CHLOROPYRIDIN-2-IL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-IL) METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOL-6-CARBOXYLIC, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT
compounds, process for their manufacture, pharmaceutical compositions comprising them, method for the treatment and / or prophylaxis of diseases that are associated with the glucagon receptor and their use
ENANTIOMER [R] PURE 5 - {[2-FLUORO-4- (2-OXO-2H-PIRIDIN-1-IL) -PENYL] -AMIDA} 1 - [(4-CHLORINE-PHENYL) -AMIDE] OF THE ACID [R] -5-METHYL-4, 5-DIHIDRO-PIRAZOL-1, 5-DICARBOXILICO, A METHOD FOR THE PREPARATION OF THE COMPOSITE MENTIONED, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, CRYSTALLINE FORMS OF THE SAME AND
PROCEDURE FOR THE PREPARATION OF (3S) -3- (4-CHLORO-3 - {[(2S, 3R) -2- (4-CHLOROPHENYL) -4,4,4-TRIFLUOR-3- METHYLBUTANOYL] AMINO} PHENYL) -3-CYCLOPROPILPROPANOIC ACID AND ITS CRYSTAL FORM FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE.
SOLID FORMS OF 2-[3-[4-AMINO-3-(2-FLUORINE-4-PHENOXY-PHENYL)PYRAZOLE[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL -4-[4-(OXETAN-3-IL)PIPERAZIN-1-IL]PENT-2-ENENITRILE